Technology
Health
Biotechnology
Radius Health
$18.729876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$18.72
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.05 (0.27%) Today
+$0.05 (0.27%) Today
Why Robinhood?
You can buy or sell Radius Health and other stocks, options, ETFs, and crypto commission-free!
About
Radius Health, Inc. Common Stock, also called Radius Health, is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. Read More The company's lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes abaloparatide transdermal patch for potential use in osteoporosis and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Waltham, MA.
Employees
398
Headquarters
Waltham, Massachusetts
Founded
2003
Market Cap
850.67M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
762.50K
High Today
$18.91
Low Today
$18.63
Open Price
$18.67
Volume
42.84K
52 Week High
$37.66
52 Week Low
$12.81
Collections
Technology
Health
Biotechnology
Biopharmaceutical
Therapy
Cancer Prevention
Pharmaceutical
2014 IPO
News
Yahoo FinanceMar 1
Radius (RDUS) Posts Narrower Q4 Loss on Robust Tymlos Sales
Radius Health, Inc. RDUS reported encouraging results for the fourth quarter of 2018, wherein loss was narrower than expected and sales beat estimates. Radius Health, Inc. Price, Consensus and EPS Surprise Radius Health, Inc. Price, Consensus and EPS Surprise | Radius Health, Inc. Quote The company reported a loss of $0.66 per share in the quarter, narrower than both the Zacks Consensus Estimate of a loss of $0.82 and the year-ago period’s loss of $1.36. Increase in revenues led to the narrower-than-anti...
Price Paid on Robinhood
28% Lower
Right Now
52 Week Low
$12.81
Average Price Paid
$25.93
52 Week High
$37.66
Earnings
-$1.59
-$1.28
-$0.97
-$0.66
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
—
Actual
Expected May 9, After Hours